Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM7U2BE)

Drug Name
Alloxazine Drug Info
Synonyms
Alloxazine; Isoalloxazine; 490-59-5; Alloxazin; benzo[g]pteridine-2,4(1H,3H)-dione; 1H-Benzo[g]pteridine-2,4-dione; Benzo(g)pteridine-2,4(1H,3H)-dione; UNII-880W3VF9YW; benzo[g]pteridine-2,4(3H,10H)-dione; CHEMBL68500; 880W3VF9YW; CHEBI:37325; HAUGRYOERYOXHX-UHFFFAOYSA-N; Benzo[g]pteridine-2,4[1H,3H]-dione; 1H,2H,3H,4H-benzo[g]pteridine-2,4-dione; Benzo[g]pteridine-2,3H)-dione; WLN: T C666 BN DMVMV INJ; 1,3-dihydrobenzo[g]pteridine-2,4-dione; SR-01000075199; Alloxazine, 96%; EINECS 207-714-3; NSC 203056; AC1NSYUA; Lopac-A-242
Cross-matching ID
PubChem CID
5372720
ChEBI ID
CHEMBL37325
CAS Number
CAS 490-59-5
TTD Drug ID
D0Y5TL

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Graft-versus-host disease 2.31 0.00e+0 32/42 (76.19%) GZMB;PRF1;HLA-C;...
Allograft rejection 2.19 0.00e+0 32/38 (84.21%) GZMB;PRF1;HLA-C;...
Viral protein interaction with cytokine and cytokine re... 2.17 0.00e+0 84/100 (84%) CXCL10;CXCL13;TNFSF10;...
Cytosolic DNA-sensing pathway 1.99 0.00e+0 52/63 (82.54%) CXCL10;CCL5;IKBKE;...
Systemic lupus erythematosus 1.92 2.01e-3 45/135 (33.33%) C1S;C1R;C1QA;...
DNA replication 1.89 3.34e-3 34/36 (94.44%) MCM6;RFC2;PCNA;...
Chemokine signaling pathway 1.88 2.86e-3 163/192 (84.9%) CXCL10;CXCL13;CXCL9;...
Type I diabetes mellitus 1.85 2.51e-3 38/43 (88.37%) GZMB;PRF1;HLA-C;...
Pertussis 1.85 2.23e-3 64/76 (84.21%) CD14;C1S;C1R;...
Autoimmune thyroid disease 1.84 4.01e-3 46/53 (86.79%) GZMB;PRF1;HLA-C;...
Cytokine-cytokine receptor interaction 1.83 3.65e-3 246/295 (83.39%) CXCL10;CXCL13;TNFSF10;...
Influenza A 1.80 7.52e-3 156/172 (90.7%) CXCL10;TNFSF10;CCL5;...
Toll-like receptor signaling pathway 1.77 1.16e-2 94/104 (90.38%) CXCL10;CXCL9;CD14;...
RIG-I-like receptor signaling pathway 1.74 1.29e-2 64/70 (91.43%) CXCL10;IKBKE;ATG5;...
Nucleotide excision repair 1.67 3.21e-2 40/47 (85.11%) RFC2;RAD23B;PCNA;...
Herpes simplex virus 1 infection 1.67 3.01e-2 165/498 (33.13%) SRC;CCL5;IKBKE;...
Necroptosis 1.63 4.25e-2 113/159 (71.07%) TNFSF10;HMGB1;CASP1;...
Viral carcinogenesis 1.62 4.23e-2 149/203 (73.4%) DNAJA3;SRC;CDC20;...
Base excision repair 1.61 4.80e-2 29/33 (87.88%) HMGB1;PCNA;FEN1;...
Fatty acid elongation -1.85 3.99e-2 19/27 (70.37%) HADH;HACD1;ELOVL1;...
Collecting duct acid secretion -1.95 1.99e-2 22/27 (81.48%) CLCNKB;SLC12A7;ATP6V1C1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H